EMA
Emera Incorporated
$54.34
+0.76
(+1.42%)
Mkt Cap
16.62B
Volume
205,253
52W Range
45.77-55.42
Sector
Utilities
Beta
0.45
EPS (TTM)
3.28
P/E Ratio
16.57
Revenue (TTM)
8.59B
Rev Growth (5Y)
+8.6%
EPS Growth (5Y)
-2.2%
AlphaVal · Fair Value
What we estimate one share is worth
$38.39
Overvalued
strong signal
41.5% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
D
Stable Earnings Power
36.0 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Emera Incorporated, an energy and services company, invests in generation, transmission, and distribution of electricity in the United States, Canada, Barbados, and the Bahamas. The company operates through Florida Electric Utility, Canadian Electric Utilities, Gas Utilities and Infrastructure, Other Electric Utilities, and Other segments. It is involved in the purchase, transmission, distribution, and sale of natural gas; and physical energy marketing, trading, and other energy asset management activities. The company was incorporated in 1998 and is headquartered in Halifax, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.30B | 7.20B | 7.56B | 7.59B | 5.76B | 5.51B | 6.11B | 6.52B | 6.23B | 4.28B | 2.79B | 2.94B |
| Net Income | 1.09B | 567.00M | 1.04B | 1.01B | 560.00M | 983.00M | 708.00M | 746.00M | 294.00M | 255.00M | 427.00M | 432.90M |
| EPS | 3.39 | 1.71 | 3.57 | 3.56 | 1.98 | 3.79 | 2.76 | 3.20 | 1.25 | 1.33 | 2.72 | 2.84 |
| Free Cash Flow | (1.73B) | (505.00M) | (696.00M) | (1.68B) | (1.17B) | (986.00M) | (970.00M) | (472.00M) | (336.00M) | 22.00M | 247.00M | 333.40M |
| FCF / Share | -5.78 | -1.75 | -2.54 | -6.34 | -4.56 | -3.98 | -4.04 | -2.03 | -1.57 | 0.13 | 1.69 | 2.33 |
| Operating CF | 1.80B | 2.65B | 2.24B | 913.00M | 1.19B | 1.64B | 1.52B | 1.69B | 1.19B | 1.05B | 674.20M | 762.50M |
| Total Assets | 44.78B | 42.95B | 39.48B | 39.74B | 34.24B | 31.23B | 24.56B | 32.31B | 28.77B | 29.22B | 12.01B | 9.84B |
| Total Debt | 21.62B | 19.81B | 19.80B | 19.04B | 16.40B | 15.41B | 12.17B | 16.60B | 15.12B | 15.71B | 4.77B | 4.01B |
| Cash & Equiv | 364.70M | 196.00M | 567.00M | 310.00M | 394.00M | 220.00M | 210.53M | 273.00M | 438.00M | 404.00M | 1.07B | 221.10M |
| Book Value | 13.37B | 13.28B | 12.07B | 11.43B | 10.12B | 9.20B | 6.61B | 8.32B | 7.09B | 6.70B | 4.20B | 3.40B |
| Return on Equity | 0.08 | 0.04 | 0.09 | 0.09 | 0.06 | 0.11 | 0.11 | 0.09 | 0.04 | 0.04 | 0.10 | 0.13 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.48B | 2.02B | 2.11B | 1.99B | 2.68B | 1.76B | 1.80B | 1.62B | 2.02B | 1.97B | 1.74B | 1.42B |
| Net Income | 583.50M | 86.93M | 247.00M | 154.00M | 601.00M | 173.00M | 22.00M | 147.00M | 225.00M | 307.00M | 117.00M | 44.00M |
| EPS | 1.85 | 0.22 | 0.76 | 0.45 | 1.96 | 0.52 | 0.01 | 0.45 | 0.73 | 1.04 | 0.37 | 0.16 |
| Free Cash Flow | (103.52M) | (753.39M) | (55.00M) | (896.00M) | (25.00M) | (234.00M) | (117.00M) | (122.00M) | (32.00M) | (451.00M) | 155.00M | (216.00M) |
| FCF / Share | -0.34 | -2.50 | -0.17 | -3.00 | -0.08 | -0.79 | -0.40 | -0.42 | -0.11 | -1.62 | 0.57 | -0.79 |
| Operating CF | 528.41M | 211.83M | 791.00M | 100.00M | 699.00M | 694.00M | 759.00M | 624.00M | 569.00M | 423.00M | 867.00M | 498.00M |
| Total Assets | 34.55B | 44.78B | 43.80B | 42.53B | 43.62B | 42.95B | 39.67B | 39.78B | 40.03B | 39.48B | 28.82B | 29.02B |
| Total Debt | 17.22B | 21.62B | 20.64B | 20.16B | 20.08B | 19.81B | 18.67B | 19.55B | 19.98B | 19.80B | 14.42B | 14.63B |
| Cash & Equiv | 1.78B | 364.70M | 212.00M | 200.00M | 308.00M | 196.00M | 240.00M | 348.00M | 276.00M | 567.00M | 200.96M | 252.72M |
| Book Value | 10.20B | 13.37B | 13.47B | 13.15B | 13.73B | 13.28B | 12.43B | 12.55B | 12.43B | 12.07B | 8.66B | 8.74B |
| Return on Equity | 0.06 | 0.01 | 0.02 | 0.01 | 0.04 | 0.01 | 0.00 | 0.01 | 0.02 | 0.03 | 0.01 | 0.01 |
EMA News
CORRECTING and REPLACING Emera Declares Quarterly Dividends
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
Emera Declares Quarterly Dividends
Emera Teleconference on August 7 to Discuss Q2 2026 Results
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility